Clinic of Oncology Clinical Center Nis

Serbia

Clinic of Oncology Clinical Center Nis

Serbia
SEARCH FILTERS
Time filter
Source Type

Cvetanovic A.,Clinic of Oncology Clinical Center Nis | Vrbic S.,Clinic of Oncology Clinical Center Nis | Vrbic S.,University of Niš | Filipovic S.,Clinic of Oncology Clinical Center Nis | And 7 more authors.
Journal of B.U.ON. | Year: 2014

Purpose: To evaluate the clinical benefits of cetuximab (CTX) and the prognostic value of CTX-related skin toxicity in metastatic colorectal cancer (mCRC) patients. Methods: Sixty patients were tested for KRAS mutation at the Department of Oncology, Clinical Centre Nis. We assessed 34 wild-type KRAS mCRC patients treated with CTX. All of them were refractory to prior fluoropyrimidine, oxaliplatin and irinotecan-based regimens. The maximum grade skin toxicity according to treatment cycle was analyzed. Skin toxicity was grouped into clinically non-relevant skin toxicity (grade 0 -1: Group 1) and clinically relevant skin toxicity (grade 2-4: Group 2). Results: Ten out of 33 patients (30.30%) achieved partial response (PR). Eight additional patients (24.24%) showed stable disease (SD), whereas 15 (45.45%) had disease progression (PD). No patient achieved complete response (CR). Overall response rate (ORR) was 30.30%, whereas the disease control rate (DCR) was 54.54%.The median progression free survival (PFS) was 14 weeks. Some degree of skin toxicity was observed in 79.41% (27/34) of the patients. Clinically non-relevant skin toxicity was observed in 50% (17/34), and clinically relevant in 50% (17/34) of the patients. Grade 4 skin toxicity was documented in 1 patient. The mean PFS in Group 1 was 12.65±5.59 weeks and in Group 2 22.82±12.16 (p<0.05). The results showed that grade 2-4 skin toxicity was associated with significantly better response to treatment than skin toxicity grade 0-1, with regard to ORR (80.00 vs 20.00%; p<0.05) and DCR ( 66.66 vs 33.33%; p<0.05). Conclusion: Cetuximab has clinical benefit when given alone or in combination with irinotecan in patients with irinotecan-refractory CRC. Skin toxicity was one of the predictors of response and it was in line with what was expected.

Loading Clinic of Oncology Clinical Center Nis collaborators
Loading Clinic of Oncology Clinical Center Nis collaborators